MCRB Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Seres Therapeutics's net margin of --. Seres Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Seres Therapeutics has a consensus price target of $4.08, signalling upside risk potential of 921.09%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 677.99%. Given that Seres Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Seres Therapeutics is more attractive than Perspective Therapeutics.

Seres Therapeutics has a beta of 2.541, which suggesting that the stock is 154.129% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Seres Therapeutics's net income of -$15.6M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.50x versus 11.98x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Cellectar Biosciences has a net margin of -- compared to Seres Therapeutics's net margin of --. Seres Therapeutics's return on equity of -- beat Cellectar Biosciences's return on equity of --.

Seres Therapeutics has a consensus price target of $4.08, signalling upside risk potential of 921.09%. On the other hand Cellectar Biosciences has an analysts' consensus of $5.67 which suggests that it could grow by 1900.94%. Given that Cellectar Biosciences has higher upside potential than Seres Therapeutics, analysts believe Cellectar Biosciences is more attractive than Seres Therapeutics.

Seres Therapeutics has a beta of 2.541, which suggesting that the stock is 154.129% more volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.203%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than Cellectar Biosciences quarterly revenues of --. Seres Therapeutics's net income of -$15.6M is lower than Cellectar Biosciences's net income of -$2.4M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.50x versus 730.55x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Seres Therapeutics's net margin of -49.65%. Seres Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Seres Therapeutics has a consensus price target of $4.08, signalling upside risk potential of 921.09%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Seres Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Seres Therapeutics is more attractive than NovaBay Pharmaceuticals.

Seres Therapeutics has a beta of 2.541, which suggesting that the stock is 154.129% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Seres Therapeutics's net income of -$15.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.50x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals has a net margin of -- compared to Seres Therapeutics's net margin of -1226.16%. Seres Therapeutics's return on equity of -- beat Syndax Pharmaceuticals's return on equity of -74.65%.

Seres Therapeutics has a consensus price target of $4.08, signalling upside risk potential of 921.09%. On the other hand Syndax Pharmaceuticals has an analysts' consensus of $35.25 which suggests that it could grow by 219.01%. Given that Seres Therapeutics has higher upside potential than Syndax Pharmaceuticals, analysts believe Seres Therapeutics is more attractive than Syndax Pharmaceuticals.

Seres Therapeutics has a beta of 2.541, which suggesting that the stock is 154.129% more volatile than S&P 500. In comparison Syndax Pharmaceuticals has a beta of 1.281, suggesting its more volatile than the S&P 500 by 28.116%.

Seres Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics pays -- of its earnings as a dividend. Syndax Pharmaceuticals pays out -- of its earnings as a dividend.

Seres Therapeutics quarterly revenues are --, which are smaller than Syndax Pharmaceuticals quarterly revenues of $7.7M. Seres Therapeutics's net income of -$15.6M is higher than Syndax Pharmaceuticals's net income of -$94.2M. Notably, Seres Therapeutics's price-to-earnings ratio is -- while Syndax Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics is 0.50x versus -- for Syndax Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.